{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:24Z","timestamp":1787027064975,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Roflumilast is an option for treating patients with severe COPD and frequent exacerbations despite optimal therapy with inhaled drugs. The present study focused on whether the phosphodiesterase (PDE) 4 inhibitor roflumilast and its active metabolite roflumilast N-oxide affect the release of tumor necrosis factor (TNF)-\u03b1 and chemokines by lipopolysaccharide (LPS)-stimulated human bronchial explants. We also investigated the interactions between roflumilast, roflumilast N-oxide and the \u03b2\n                    <jats:sub>2<\/jats:sub>\n                    -agonist formoterol with regard to cytokine release by the bronchial preparations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Bronchial explants from resected lungs were incubated with roflumilast, roflumilast N-oxide and\/or formoterol and then stimulated with LPS. An ELISA was used to measure levels of TNF-\u03b1 and chemokines in the culture supernatants.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    At a clinically relevant concentration (1\u00a0nM), roflumilast N-oxide and roflumilast consistently reduced the release of TNF-\u03b1, CCL2, CCL3, CCL4, CCL5 and CXCL9 (but not CXCL1, CXCL5, CXCL8 and IL-6) from human bronchial explants. Formoterol alone decreased the release of TNF-\u03b1, CCL2, and CCL3. The combination of formoterol with roflumilast (1\u00a0nM) was more potent than roflumilast alone for inhibiting the LPS-induced release of TNF-\u03b1, CCL2, CCL3, CCL4, and CXCL9 by the bronchial explants.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    At a clinically relevant concentration, roflumilast N-oxide and its parent compound, roflumilast, reduced the LPS-induced production of TNF-\u03b1 and chemokines involved in monocyte and T-cell recruitment but did not alter the release of chemokines involved in neutrophil recruitment. The combination of formoterol with roflumilast enhanced the individual drugs\u2019 anti-inflammatory effects.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2020.598702","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T07:57:30Z","timestamp":1607414250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist"],"prefix":"10.3389","volume":"11","author":[{"given":"H\u00e9l\u00e8ne","family":"Salvator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Buenestado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Brollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Naline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Victoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Longchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Tenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Grassin-Delyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.pupt.2015.08.006","article-title":"Roflumilast for asthma: efficacy findings in mechanism of action studies","volume":"35","author":"Bardin","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1165\/rcmb.2009-0220TR","article-title":"The cytokine network in chronic obstructive pulmonary disease","volume":"41","author":"Barnes","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.pupt.2015.10.002","article-title":"Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies","volume":"35","author":"Bateman","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2015.11.035","article-title":"Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma","volume":"138","author":"Bateman","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting \u03b22-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur. Respir. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1165\/rcmb.2007-0171OC","article-title":"A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells","volume":"38","author":"Billington","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B9","first-page":"7361","article-title":"The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages","volume":"176","author":"Bryn","year":"2006","journal-title":"J. Immunol. Baltim. Md."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e74640","DOI":"10.1371\/journal.pone.0074640","article-title":"Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-\u03b1 and chemokine production by human lung parenchyma","volume":"8","author":"Buenestado","year":"2013","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1476-5381.2009.00614.x","article-title":"The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages","volume":"159","author":"Buenestado","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/j.1476-5381.2011.01667.x","article-title":"Roflumilast inhibits the release of chemokines and TNF-\u03b1 from human lung macrophages stimulated with lipopolysaccharide","volume":"165","author":"Buenestado","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1476-5381.1993.tb12841.x","article-title":"Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus","volume":"108","author":"Cortijo","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1476-5381.1992.tb14451.x","article-title":"Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors","volume":"106","author":"de Boer","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/pupt.1998.0115","article-title":"Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors","volume":"11","author":"Dent","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1183\/09031936.00158008","article-title":"Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages","volume":"36","author":"Donnelly","year":"2010","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1165\/rcmb.2018-0065OC","article-title":"Direct inhibitory effect of the PDE4 inhibitor roflumilast on neutrophil migration in chronic obstructive pulmonary disease","volume":"60","author":"Dunne","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jcp.54.2.107","article-title":"Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid","volume":"54","author":"Flanagan","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1165\/ajrcmb.20.2.3140","article-title":"Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells","volume":"20","author":"Fuhrmann","year":"1999","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","first-page":"1273","article-title":"Synergistic interactions of fungicides in mixtures","volume":"86","author":"Gisi","year":"1996","journal-title":"Phytopathology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12931-020-1329-y","article-title":"Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis","volume":"21","author":"Govoni","year":"2020","journal-title":"Respir. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1094-5539(03)00090-7","article-title":"Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)","volume":"16","author":"Grootendorst","year":"2003","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"B25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/sj.bjp.0703866","article-title":"beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells","volume":"132","author":"Hallsworth","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.rmed.2013.09.018","article-title":"Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD","volume":"108","author":"Hanania","year":"2014","journal-title":"Respir. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-200746050-00003","article-title":"Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis","volume":"46","author":"Hermann","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.pupt.2008.02.002","article-title":"Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial","volume":"21","author":"Hohlfeld","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1476-5381.2010.00708.x","article-title":"Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action","volume":"160","author":"Holden","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD002309","DOI":"10.1002\/14651858.CD002309.pub6","article-title":"Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease","volume":"5","author":"Janjua","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"L505","DOI":"10.1152\/ajplung.00046.2008","article-title":"Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A","volume":"295","author":"Kaur","year":"2008","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.2147\/COPD.S167730","article-title":"Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK","volume":"13","author":"Kiff","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1183\/09031936.01.00073301","article-title":"Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells","volume":"17","author":"Korn","year":"2001","journal-title":"Eur. Respir. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2165\/11536600-000000000-00000","article-title":"Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model","volume":"49","author":"Lahu","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"154739","DOI":"10.1016\/j.cyto.2019.154739","article-title":"The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients","volume":"123","author":"Lea","year":"2019","journal-title":"Cytokine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1164\/ajrccm.155.3.9117029","article-title":"Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome","volume":"155","author":"Martin","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1164\/rccm.201712-2493OC","article-title":"Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials","volume":"198","author":"Martinez","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.pupt.2015.10.006","article-title":"Roflumilast for asthma: efficacy findings in placebo-controlled studies","volume":"35","author":"Meltzer","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/ajrccm\/146.2.427","article-title":"Elevated levels of NAP-1\/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality","volume":"146","author":"Miller","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CLEP.S16235","article-title":"Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis","volume":"3","author":"Mills","year":"2011","journal-title":"Clin. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1165\/rcmb.2007-0232OC","article-title":"EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17","volume":"38","author":"Morin","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.niox.2003.07.001","article-title":"Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kappaB in alveolar epithelial cell line: role of reactive oxygen\/nitrogen species and cytokines","volume":"9","author":"Nys","year":"2003","journal-title":"Nitric Oxide Biol. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/thorax.58.7.573","article-title":"Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD","volume":"58","author":"Profita","year":"2003","journal-title":"Thorax"},{"key":"B45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","article-title":"Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial","volume":"6","author":"Rabe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1084\/jem.162.6.1904","article-title":"Studies on the release of leukotrienes and histamine by human lung parenchymal and bronchial fragments upon immunologic and nonimmunologic stimulation. Effects of nordihydroguaiaretic acid, aspirin, and sodium cromoglycate","volume":"162","author":"Salari","year":"1985","journal-title":"J. Exp. Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12626","article-title":"Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist","author":"Salvator","year":"2020","journal-title":"Fundamental Clin. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.bjp.0707428","article-title":"Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability","volume":"152","author":"Sanz","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respir. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2016.06.011","article-title":"A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients","volume":"40","author":"Singh","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2000237","DOI":"10.1183\/13993003.00237-2020","article-title":"COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition","volume":"56","author":"Singh","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/thorax.57.3.237","article-title":"Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts","volume":"57","author":"Spoelstra","year":"2002","journal-title":"Thorax"},{"key":"B52","doi-asserted-by":"publisher","first-page":"44147","DOI":"10.1074\/jbc.M204810200","article-title":"Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor","volume":"277","author":"Takayama","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/00912700222011328","article-title":"The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo","volume":"42","author":"Timmer","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"B54","first-page":"1213","article-title":"Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle","volume":"265","author":"Torphy","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1465-9921-14-127","article-title":"Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle","volume":"14","author":"Van Ly","year":"2013","journal-title":"Respir. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12931-017-0613-y","article-title":"Human lung and monocyte-derived macrophages differ with regard to the effects of \u03b22-adrenoceptor agonists on cytokine release","volume":"18","author":"Victoni","year":"2017","journal-title":"Respir. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1164\/rccm.201503-0543OC","article-title":"A randomized, placebo-controlled trial of roflumilast. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease","volume":"192","author":"Wells","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1111\/bph.13143","article-title":"The long-acting \u03b22 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation","volume":"172","author":"Wex","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"L643","DOI":"10.1152\/ajplung.00373.2013","article-title":"cAMP-dependent protein kinase activation decreases cytokine release in bronchial epithelial cells","volume":"307","author":"Wyatt","year":"2014","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s0306-3623(96)00580-0","article-title":"Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells","volume":"29","author":"Yoshimura","year":"1997","journal-title":"Gen. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"L441","DOI":"10.1152\/ajplung.00407.2010","article-title":"NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues","volume":"301","author":"Yougbare","year":"2011","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.598702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T07:57:33Z","timestamp":1607414253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.598702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":62,"alternative-id":["10.3389\/fphar.2020.598702"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.598702","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"article-number":"598702"}}